NO20090238L - Anvendelse av tymosin-α 1 for fremstilling av et medikament for behandling av trinn IV ondartet melanom - Google Patents
Anvendelse av tymosin-α 1 for fremstilling av et medikament for behandling av trinn IV ondartet melanomInfo
- Publication number
- NO20090238L NO20090238L NO20090238A NO20090238A NO20090238L NO 20090238 L NO20090238 L NO 20090238L NO 20090238 A NO20090238 A NO 20090238A NO 20090238 A NO20090238 A NO 20090238A NO 20090238 L NO20090238 L NO 20090238L
- Authority
- NO
- Norway
- Prior art keywords
- stage
- treatment
- thymosin
- malignant melanoma
- drug
- Prior art date
Links
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 201000001441 melanoma Diseases 0.000 title abstract 2
- 108010078233 Thymalfasin Proteins 0.000 title 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 title 1
- 229960004231 thymalfasin Drugs 0.000 title 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 abstract 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 102000007501 Thymosin Human genes 0.000 abstract 1
- 108010046075 Thymosin Proteins 0.000 abstract 1
- 229960003901 dacarbazine Drugs 0.000 abstract 1
- 229950000038 interferon alfa Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/32—Thymopoietins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/424,475 US20070292392A1 (en) | 2006-06-15 | 2006-06-15 | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma |
| US11/734,592 US8017129B2 (en) | 2006-06-15 | 2007-04-12 | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma |
| PCT/EP2007/053712 WO2007144218A1 (en) | 2006-06-15 | 2007-04-17 | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20090238L true NO20090238L (no) | 2009-03-10 |
Family
ID=38323947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20090238A NO20090238L (no) | 2006-06-15 | 2009-01-14 | Anvendelse av tymosin-α 1 for fremstilling av et medikament for behandling av trinn IV ondartet melanom |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8017129B2 (https=) |
| EP (1) | EP2032153A1 (https=) |
| JP (1) | JP2009539916A (https=) |
| KR (1) | KR20090020646A (https=) |
| AR (1) | AR061352A1 (https=) |
| AU (1) | AU2007260145A1 (https=) |
| CA (1) | CA2652516A1 (https=) |
| HR (1) | HRP20090010A2 (https=) |
| IL (1) | IL195955A0 (https=) |
| MX (1) | MX2008015145A (https=) |
| NO (1) | NO20090238L (https=) |
| RU (1) | RU2009101026A (https=) |
| TW (1) | TW200808327A (https=) |
| WO (1) | WO2007144218A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7260764B2 (en) * | 2002-11-26 | 2007-08-21 | Qualcomm Incorporated | Multi-channel transmission and reception with block coding in a communication system |
| US20080300166A1 (en) * | 2007-06-01 | 2008-12-04 | Sciclone Pharmaceuticals, Inc. | Treatment of Melanoma with Alpha Thymosin Peptides |
| US20100317583A1 (en) * | 2007-12-14 | 2010-12-16 | Sciclone Pharmaceuticals, Inc. | Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa) |
| ES2356865T3 (es) * | 2008-10-16 | 2011-04-13 | Orion Tech Anstalt | Tratamiento de residuos líquidos que contienen metales pesados. |
| CA2976062C (en) | 2015-02-09 | 2025-05-13 | Sciclone Pharmaceuticals International (Sg) Pte. Ltd. | THYMOSINE ALPHA 1 INTENDED FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS |
| US9861833B1 (en) * | 2017-03-30 | 2018-01-09 | Norman H. Anderson | Methods of treating melanoma |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5888980A (en) * | 1994-06-30 | 1999-03-30 | Bio-Logic Research And Development Corporation | Compositions for enhancing immune function |
| US5632983A (en) | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
| US5728707A (en) | 1995-07-21 | 1998-03-17 | Constantia Gruppe | Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide |
| US6462017B1 (en) * | 2000-05-01 | 2002-10-08 | Sciclone Pharmaceuticals, Inc. | Method of reducing side effects of chemotherapy in cancer patients |
| US7208167B2 (en) * | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| UA80957C2 (en) | 2001-11-01 | 2007-11-26 | Sciclone Pharmaceuticals Inc | Method of administering a thymosin alpha 1 peptide |
| UA78726C2 (en) | 2001-11-01 | 2007-04-25 | Sciclone Pharmaceuticals Inc | Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment |
| US7101598B2 (en) | 2002-05-22 | 2006-09-05 | Om Nova Solutions Inc. | Self adhering membrane for roofing applications |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| US20080300166A1 (en) | 2007-06-01 | 2008-12-04 | Sciclone Pharmaceuticals, Inc. | Treatment of Melanoma with Alpha Thymosin Peptides |
-
2007
- 2007-04-12 US US11/734,592 patent/US8017129B2/en active Active
- 2007-04-17 CA CA002652516A patent/CA2652516A1/en not_active Abandoned
- 2007-04-17 MX MX2008015145A patent/MX2008015145A/es not_active Application Discontinuation
- 2007-04-17 KR KR1020087031799A patent/KR20090020646A/ko not_active Withdrawn
- 2007-04-17 WO PCT/EP2007/053712 patent/WO2007144218A1/en not_active Ceased
- 2007-04-17 JP JP2009514721A patent/JP2009539916A/ja not_active Withdrawn
- 2007-04-17 AU AU2007260145A patent/AU2007260145A1/en not_active Abandoned
- 2007-04-17 HR HR20090010A patent/HRP20090010A2/xx not_active Application Discontinuation
- 2007-04-17 RU RU2009101026/15A patent/RU2009101026A/ru not_active Application Discontinuation
- 2007-04-17 EP EP07728177A patent/EP2032153A1/en not_active Withdrawn
- 2007-04-23 TW TW096114301A patent/TW200808327A/zh unknown
- 2007-06-13 AR ARP070102577A patent/AR061352A1/es unknown
-
2008
- 2008-12-15 IL IL195955A patent/IL195955A0/en unknown
-
2009
- 2009-01-14 NO NO20090238A patent/NO20090238L/no not_active Application Discontinuation
- 2009-03-31 US US12/415,589 patent/US8029799B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2032153A1 (en) | 2009-03-11 |
| US20070292393A1 (en) | 2007-12-20 |
| JP2009539916A (ja) | 2009-11-19 |
| US8017129B2 (en) | 2011-09-13 |
| KR20090020646A (ko) | 2009-02-26 |
| IL195955A0 (en) | 2009-09-01 |
| AU2007260145A1 (en) | 2007-12-21 |
| RU2009101026A (ru) | 2010-07-20 |
| HRP20090010A2 (en) | 2009-02-28 |
| AR061352A1 (es) | 2008-08-20 |
| CA2652516A1 (en) | 2007-12-21 |
| WO2007144218A1 (en) | 2007-12-21 |
| TW200808327A (en) | 2008-02-16 |
| US20090186000A1 (en) | 2009-07-23 |
| MX2008015145A (es) | 2008-12-15 |
| US8029799B2 (en) | 2011-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1986669T3 (pl) | Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia | |
| HRP20110969T1 (en) | Pimobendan to be used for the reduction of heart size in mammals suffering from heart failure | |
| CY1112320T1 (el) | Τιτλοδοτηση της ταπενταδολης | |
| NO20090238L (no) | Anvendelse av tymosin-α 1 for fremstilling av et medikament for behandling av trinn IV ondartet melanom | |
| CY1115180T1 (el) | Επιλογες θεραπειας για τη νοσο του fabry | |
| IL185808A0 (en) | Amide-substituted 8-n-benzimidazoles, metohd for the production thereof, and use of the same as medicaments | |
| WO2009134574A3 (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| BRPI0511615B8 (pt) | forma de administração oral compreendendo bactéria probiótica | |
| PL1799231T3 (pl) | Zastosowanie cyklodekstryny do leczenia i zapobiegania chorobom zapalnym oskrzeli | |
| IL207623A0 (en) | New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer | |
| NO20072285L (no) | S-mirtazapin for behandling av hetetokter | |
| CA118307S (en) | Pasta dispenser disk | |
| DK1781277T3 (da) | Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol | |
| NZ595364A (en) | TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION | |
| ATE540690T1 (de) | Insulinkombinationen | |
| GT200500266A (es) | Nuevos derivados de pirimidina y su uso | |
| CY1111840T1 (el) | Χρηση του 4-κυκλοπροπυλμεθοξυ-ν-(3,5-διχλωρο-1-οξειδο-πυριδιν-4-υλ)-5-(μεθοξυ)πυριδιν-2-καρβοξαμιδιου για τη θεραπεια κινητικων διαταραχων που σχετιζονται με τη νοσο toy parkinson | |
| DK1713438T3 (da) | Medicinsk sæbe | |
| AR067351A1 (es) | Combinacion de picotamida con nafronil | |
| CY1118581T1 (el) | Νεα χρηση για αλφα-συμπαθομιμητικα με δομη 2-ιμιδαζολινης | |
| TW200613343A (en) | Novel prepolymers for improved surface modification of contact lenses | |
| ZA200900257B (en) | Use of thymosin Alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma | |
| DK1962822T3 (da) | Terapi af maligne neoplasier | |
| ITFI20060268A1 (it) | Una scaffalatura del tipo utilizzato da negozi, supermercati e simili | |
| AU326757S (en) | Base plate element for decorations or ornaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |